ki:elements

Optimize your Alzheimer's study: Get the new white paper on avoiding trial pitfalls

Projects

&

studies
Our current

projects & studies

ReTain

The ReTain trial is Phase 2b trial collaboration between kiːelements and Johnson & Johnson, focused on evaluating the safety and effectiveness of an investigational medicine for early Alzheimer’s Disease.

See more about the project

Pre-screening for potential eligibility for AD studies

This trial, in collaboration with Roche, is a global, multi-site screening study to assess participants’ potential for Roche’s Alzheimer’s studies. 

See more about the project

T01- Digital biomarkers for speech changes in Parkinson's Disease

This project aims to develop an algorithm that reliably detects clinically relevant speech changes in Parkinson’s disease. 

See more about the project

PROSA

PROSA, in collaboration with DZNE, aims at the development and validation of a new prognostic language biomarker for the ALS-FTD spectrum based on repeatable, short, high-frequency speech assessments that can be collected remotely.

See more about the project

PROSPECT-AD

PROSPECT-AD aims to scale speech-based cognitive tests that can be conducted over the phone to screen and monitor preclinical Alzheimer’s Disease.
See more about the project

Global Cohorts - Davos Alzheimer's Collaborative

A global initiative by the Davos Alzheimer’s Collaborative aims to deploy the Speech Biomarker for Cognition (SB-C) in both large clinical trial sites as well as remote locations.

See more about the project